Discover Your Next Immunotherapy Biomarker with Quantitative Adaptive Immune Repertoire Profiling
- PCR amplification artifacts and sequencing noise can obscure true biological signals.
- Highly diverse repertoires introduce sampling bias and reproducibility challenges.
- Extracting interpretable patterns from large, complex AIRR datasets requires bioinformatics capabilities that most teams don’t have in-house.
Track T-Cell Repertoire Dynamics to Reveal Immunotherapy Response Biomarkers
Detecting TCR repertoire remodeling in patients who don't respond to standard immunotherapy
As immuno-oncology enters a precision era, the demand for biomarkers that explain response, resistance, and durability has grown rapidly. Yet commonly used markers such as PD-L1 expression or tumor mutational burden often fail to fully predict clinical outcomes. See how our platform enabled product characterization, clonal tracking, and mechanistic biomarker generation in patients with metastatic non-small cell lung cancer.
Key findings:
- Post-infusion peripheral blood clonality more closely resembled the TIL product than pre-infusion blood, confirming TCR repertoire remodeling driven by the therapy
- TIL product clone expansion was detected in post-infusion blood across patient subgroups, including those with resistance-associated tumor profiles
- iRepertoire’s technology enables precision medicine through highly accurate TCR/BCR sequencing and comprehensive, quantitative data analysis tailored for biomarker detection
See how precise, quantitative AIRR analysis turns clonal dynamics and repertoire remodeling into clinically actionable biomarkers
CRISPR-Cas9 CISH-knockout TIL therapy achieves complete response in immunotherapy-resistant metastatic colorectal cancer
Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited TILs in patients with metastatic colorectal cancer.
iRepertoire TCR profiling confirmed TIL polyclonality and neoantigen specificity in the first-in-human phase 1 trial of CISH-knockout cell therapy.
TCR repertoire profiling characterizes clonal dynamics and persistence in autologous TIL therapy for mNSCLC
Lifileucel, an autologous TIL monotherapy, was evaluated in patients with advanced NSCLC resistant to immune checkpoint inhibitors. RepSeq enabled product QC and quantitative TCR clonotype tracking, supporting mechanistic biomarker development in a Phase 2 clinical trial.
Seven-chain adaptive immune receptor repertoire analysis in rheumatoid arthritis reveals novel features associated with disease and clinically relevant phenotypes
Comprehensive 7-chain AIRR analysis of samples obtained from RA patients revealed disease-associated clonal signatures and diversity indices as potential biomarkers across a large patient cohort. Data showed clear differences between therapeutic responders and non-responders.
Immune repertoire profiling reveals TCR signatures associated with clinical outcomes following immune checkpoint inhibitor treatment
Immune repertoire profiling of pre- and post-treatment samples identified novel TCR signatures associated with positive clinical outcomes in ICI-treated (immune checkpoint inhibitor) patients.
Explore our services
Bulk immune repertoire profiling
Discover RepSeq+, our sensitive, quantitative, and high-throughput assay that combines multiplex PCR with NGS to analyze any combination of all seven chains of the adaptive immune system in a single reaction.
Single cell V(D)J profiling
Explore iPair, the first commercialized technology for capturing physically paired full-length V(D)J sequences in TCRs or BCRs from FACS isolated single cells in the same reaction well.
Data Analysis
Leverage our built-for-purpose, advanced AIRR analysis tools that translate raw sequence data into actionable insights.
Additional resources
Ready to get started?
iRepertoire serves as a leader in the field of immune repertoire profiling. We invite you to consult with our team of scientists to discover how our services can accelerate your analysis of immune cell function and diversity.